Genetic Panel Reveals Coexisting Neuromuscular Disorders in Patients With Duchenne Muscular Dystrophy.

This article focuses on the identification and clinical implications of secondary neuromuscular disorders in patients with Duchenne muscular dystrophy (DMD), a severe X-linked neuromuscular disorder characterized by progressive muscle degeneration and cardiomyopathy. Reviewing genetic panels from 353 patients, the study found that 9.4% of those with DMD also had genetically confirmed secondary neuromuscular disorders, including nemaline myopathy, titinopathy, Pompe disease, and myotonia congenita. The presence of these coexisting conditions may complicate clinical diagnosis, affect treatment efficacy, and influence outcomes in pharmaceutical clinical trials, underscoring the need for comprehensive genetic testing beyond single-gene analysis before treatment planning or trial enrollment. The findings also highlight potential benefits for family counseling and the importance of integrating expanded genetic insights into clinical practice to optimize patient care.